[1]
American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care, 2009 b, 32(1), S62-S67.
[2]
Pucci, G.; Alcidi, R.; Tap, L.; Battista, F.; Mattace-Raso, F.; Schillaci, G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol. Res., 2017, 120, 34-42.
[3]
Day, C.P. From fat to inflammation. Gastroenterology, 2006, 130, 207-210.
[4]
Florez, H.; Silva, E.; Fernández, V.; Ryder, E.; Sulbarán, T.; Campos, G.; Calmón, G.; Clavel, E.; Castillo-Florez, S.; Goldberg, R. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res. Clin. Pract., 2005, 69(1), 63-77.
[5]
Abdeldyem, S.M.; Goda, T.; Khodeir, S.A.; Abou Saif, S.; Abd-Elsalam, S. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J. Clin. Lipidol., 2017, 11(4), 915-919.
[6]
Lu, F.H.; Ou, H.Y.; Wu, H.T.; Hung, H.C.; Wu, J.S.; Yang, Y.C.; Chang, C.J. Serum Horm. Metab. Res.,2018, 50, 397-402.hepassocin concentrations in diabetic patients with or without nonalcoholic fatty liver disease. Diabetes Management, 2014, 4, 255-261.
[7]
Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Bugianesi, E.; Lenzi, M.; McCullough, A.J.; Natale, S.; Forlani, G.; Melchionda, N. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes, 2001, 50, 1844-1850.
[8]
Sheng, X.; Che, H.; Ji, Q.; Yang, F.; Lv, J.; Wang, Y.; Xian, H.; Wang, L. The relationship between liver enzymes and insulin resistance in type 2 diabetes patients with nonalcoholic fatty liver disease. Horm. Metab. Res., 2018, 50, 397-402.
[9]
Lazo, M.; Hernaez, R.; Bonekamp, S.; Kamel, I.R.; Guallar, E.; Clark, J.M. Nonalcoholic fatty liver disease and mortality among US adults: Prospective cohort study. BMJ, 2011, 343, d6891.
[10]
Cao, M.M.; Xu, W.X.; Li, C.Y.; Cao, C.Z.; Wang, Z.D.; Yao, J.W.; Yu, M.; Zhan, Y.Q.; Wang, X.H.; Tang, L.J.; Chen, H.; Li, W.; Ge, C.H.; Yang, X.M. Hepassocin regulates cell proliferation of the human hepatic cells L02 and hepatocarcinoma cells through different mechanisms. J. Cell. Biochem., 2011, 112(10), 2882-2890.
[11]
Wu, H.T.; Lu, F.H.; Ou, H.Y.; Su, Y.C.; Hung, H.C.; Wu, J.S.; Yang, Y.C.; Wu, C.L.; Chang, C.J. The role of hepassocin in the development of non-alcoholic fatty liver disease. J. Hepatol., 2013, 59(5), 1065-1072.
[12]
Loria, P.; Lonardo, A.; Anania, F. Liver and diabetes. A vicious circle. Hepatol. Res., 2013, 43(1), 51-64.
[13]
Kleiner, D.E.; Brunt, E.M.; Van Natta, M.; Behling, C.; Contos, M.J.; Cummings, O.W.; Ferrell, L.D.; Liu, Y.C.; Torbenson, M.S.; Unalp-Arida, A.; Yeh, M.; McCullough, A.J.; Sanyal, A.J. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41, 1313-1321.
[14]
Yu, H.T.; Yu, M.; Li, C.Y.; Zhan, Y.Q.; Xu, W.X.; Li, Y.H.; Li, W.; Wang, Z.D.; Ge, C.H.; Yang, X.M. Specific expression and regulation of hepassocin in the liver and down-regulation of the correlation of HNF1alpha with decreased levels of hepassocin in human hepatocellular carcinoma. J. Biol. Chem., 2009, 284(20), 13335-13347.